Não tinha visto isso, não sei dizer do que se trata, mas parece ser o app, certo? Eu olhei apenas os resultados que foram divulgados no site. Eles costumam fazer a separação entre remédios e terapias (ventilador p.e.), ou não-medicamentos como vitaminas.
Embaixo tem a última pesquisa, do dia 7 de Maio, são 6 mil e poucos médicos:
Os tratamentos mais promissores tem sido a Gamma Globulina e o plasma. Imagino que nos hospitais de primeira linha já estejam ministrando isso. Sobre a controversa hidroxicloroquina, eis o que diz a pesquisa:
Overall usage: In Week 6, Hydroxychloroquine is still the most widely used drug following Azithromycin.
- Globally 55% of physicians report using Hydroxychloroquine. Its use in various settings breaks down as follows: 37% of physicians prescribe it outside the hospital for mild cases, 59% for moderate cases when patients get into the hospital, and 50% in the ICU.
- Usage over time: We see a 22-point increase in use from Week 1. Usage from Week 1 to Week 6 has increased significantly with 33% of physicians having used Hydroxychloroquine in Week 1 vs. 55% in Week 6.
- Geographic usage : Usage around the world varies widely; in the U.S., 46% of physicians report using it; that is significantly lower than other countries such as Italy (83%), Spain (78%), Mexico (76%), Brazil (85%), and China (62%). Usage in Great Britain is much lower at 19% and Germany at 13%.
- Efficacy: Globally 27% of physicians feel that it is highly effective. However, it is felt to be more effective outside of the hospital in mild-symptom patients (32%). This trend follows what we see in usage (higher usage in mild patients).Efficacy perceptions for Hydroxychloroquine were higher in Week 1,where physicians perceived it as the most highly effective drug.
- Safety: Despite being ranked as one of the least safe drugs (29% of physicians rated it as highly safe), it is still widely used.
Sobre os suplementos, não estou encontrando a tabela que havia visto, mas resumindo: Zinco, Vitamina D e Vitamina C são os mais comuns.